Advaxis Issued New Intellectual Property Patent
January 22, 2010 08:33 AM Eastern Time
NORTH BRUNSWICK, N.J.--(EON: Enhanced Online News)--The U.S. Patent and Trademark Office (USPTO) issued today
"Compositions and Methods for Enhancing the Immunogenicity of Antigens,” by Dr. Yvonne Paterson, et al, which is assigned
the University of Pennsylvania and licensed to Advaxis, Incorporated (OTCBB: ADXS).
Research, originating in the laboratory of Dr. Yvonne Paterson and continued at Advaxis and elsewhere, has shown that the unique
called PEST (Proline, Glutamic Acid , Serine, Threonine) is associated with therapeutic efficacy in live Listeria monocytogenes (L
engineered to secrete antigen-adjuvant fusion proteins when either LLO (listeriolysin O) or ActA are used as the adjuvant.
“As we develop the intellectual property portfolio associated with our technology, this patent integrates nicely with our LLO- and A
patents,” said Executive VP of Science and Operations Dr. John Rothman. “Our portfolio includes patents for three different attenu
strains of Listeria and two different families of fusion proteins.”
The Company’s flagship Lm strain is currently in clinical testing for human papilloma virus (HPV)-induced disease, including cancer
About Advaxis, Inc.
Based in North Brunswick, New Jersey, Advaxis is developing proprietary Listeria monocytogenes (Lm) cancer vaccines based
developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis’ scienti
board. Advaxis is developing attenuated live Lm vaccines that deliver engineered tumor antigens, which stimulate multiple simultane
mechanisms to fight cancer.
In a recent Advaxis Phase I clinical trial, a live Lm vaccine directed against the tumor-associated antigen HPV-16-E7 was safely ad
fifteen (15) women with recurrent, advanced, metastatic cancer of the cervix. Although this first trial of an Lm vaccine in humans wa
powered to prove efficacy, Advaxis believes an efficacy signal was observed